Louise Barys

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Enhancing the Small-Scale Screenable Biological Space beyond Known Chemogenomics Libraries with Gray Chemical Matter─Compounds with Novel Mechanisms from High-Throughput Screening Profiles.

Enhancing the Small-Scale Screenable Biological Space beyond Known Chemogenomics Libraries with Gray Chemical Matter─Compounds with Novel Mechanisms from High-Throughput Screening Profiles.

Journal: ACS chemical biology
Published: April 02, 2024

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.

Journal: Journal for immunotherapy of cancer
Published: August 28, 2023

Protein destabilization underlies pathogenic missense mutations in ARID1B.

Protein destabilization underlies pathogenic missense mutations in ARID1B.

Journal: Nature structural & molecular biology
Published: March 10, 2023

Cancer lineage-specific regulation of YAP responsive elements revealed through large-scale functional epigenomic screens.

Cancer lineage-specific regulation of YAP responsive elements revealed through large-scale functional epigenomic screens.

Journal: Nature communications
Published: August 18, 2022

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.

Journal: Cancer discovery
Published: February 07, 2022

PAX8 and MECOM are interaction partners driving ovarian cancer.

PAX8 and MECOM are interaction partners driving ovarian cancer.

Journal: Nature communications
Published: July 27, 2020

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.

Journal: Leukemia research
Published: July 16, 2020

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.

Journal: Oncotarget
Published: June 17, 2019

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 08, 2017

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

Journal: Cancer discovery
Published: September 09, 2016

Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.

Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.

Journal: Leukemia
Published: June 15, 2016

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.

Journal: Molecular cancer therapeutics
Published: May 26, 2015
Showing 1-12 of 14

Last Updated: 09/26/2026